Analysis
Stairmed Technology, a Shanghai-based maker of implantable brain-computer interfaces, has raised about $192.5 million in a late-stage round. The company says its total funding now stands at roughly $357.5 million, according to Dealroom.
What Stairmed does
Stairmed builds implantable brain-computer interfaces that decode neural signals into commands for external devices, aimed at restoring movement for people with high-level paralysis. Its flagship product, the WRS 01, is a 256-channel system; the company says it has placed 42 long-term implants to date, which Stairmed itself says is more than Neuralink's reported 27, though that comparison is Stairmed's own claim rather than an independently verified count. The WRS 01 has not been approved for commercial use, and Stairmed still needs to demonstrate long-term safety and clinical benefit, per Dealroom's reporting.
Stairmed's funding history
Stairmed has raised money in rapid succession over the past two years:
“The WRS 01 has not been approved for commercial use, and Stairmed still needs to demonstrate long-term safety and clinical benefit, per Dealroom's reporting.”
- Series B, February 2025 -- 350 million yuan (about $47.9 million), led by Qiming Venture Partners, OrbiMed and Lilly Asia Ventures, which it called the largest single investment in China's implantable BCI industry at the time, according to Yicai Global.
- Strategic round, April 2026 -- roughly 500 million yuan ($72.8 million), led by Alibaba, with continued participation from Tencent.
- Late-stage round, October 2026 -- $192.5 million.
Stairmed says its total funding stands at roughly $357.5 million, per Dealroom; its three disclosed rounds above add up to about $313 million, a gap the company's own reporting doesn't reconcile.
Who invested in Stairmed
Tencent, Alibaba, Geely Capital, CATL, OrbiMed, Qiming Venture Partners and Lilly Asia Ventures are all named as backers of the new round, per Dealroom; none is identified as sole lead. OrbiMed, Qiming and Lilly Asia Ventures are repeat investors from Stairmed's 2025 Series B, suggesting continued conviction from its earliest institutional backers rather than an entirely new syndicate.
The brain-computer interface market and competitors
Chinese BCI startups drew an estimated $962.5 million in combined funding in the first half of 2026, and Stairmed's new round ranks in the 99th percentile of late-stage China health-sector deals over the past four years, based on a sample of 238 rounds, per Dealroom. The jump fits a broader pattern of AI and deep-tech rounds pricing up this year, which Value Add Pulse's own funding tracker has logged across sectors well beyond China. Two comparisons stand out:
- NeuroXess -- the domestic rival disclosed a $96.3 million raise the same day Stairmed's round was reported, and already has a fully implanted system in multi-center registration trials, a regulatory step ahead of Stairmed's WRS 01.
- Neuralink -- remains the best-known international comparison point, with Dealroom crediting it with $1.3 billion raised to date; Stairmed's implant-count claim versus Neuralink is the company's own marketing framing, not a verified clinical or regulatory comparison.
The regulatory race
Stairmed's implant count and funding pace are real, but the WRS 01's path to regulatory approval -- not its valuation or backer list -- is what will determine whether the company can convert its capital lead into a commercial product. NeuroXess's head start in registration trials is a genuine competitive risk if Stairmed's own regulatory timeline slips, and neither company has yet proven the long-term safety data that regulators will require before either implant reaches patients commercially.